NCT00509236View on ClinicalTrials.gov

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)

PHASE3CompletedINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

October 19, 2007

Primary Completion Date

March 14, 2011

Study Completion Date

March 14, 2011

Conditions

Diabetes Mellitus, Type 2End-Stage Kidney Disease

Interventions

DRUG

Sitagliptin

25 mg (one 25-mg tablet) once daily

DRUG

Glipizide

2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00509236 - Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1) | Biotech Hunter | Biotech Hunter